Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
The inspection conducted by EDQM at its Visakhapatnam facility
The inspection concluded with the issuance of a form 483 with five observations
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Subscribe To Our Newsletter & Stay Updated
